Nivolumab approved by FDA for esophageal squamous cell carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Opdivo (nivolumab) was approved by FDA for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy.

Efficacy was investigated in ATTRACTION-3 (NCT02569242), a multicenter, randomized (1:1), active-controlled, open-label trial in 419 patients with unresectable advanced, recurrent, or metastatic ESCC. Patients who were refractory or intolerant to at least one fluoropyrimidine- and platinum‑based regimen received nivolumab 240 mg by intravenous infusion over 30 minutes every 2 weeks (n=210), or investigator’s choice of taxane chemotherapy consisting of docetaxel (75 mg/m2 intravenously every 3 weeks) or paclitaxel (100 mg/m2 intravenously once a week for 6 weeks followed by 1 week off) (n=209).

The major efficacy outcome measure was overall survival. Additional efficacy outcome measures were overall response rate, response duration, and progression-free survival as assessed by the investigator using RECIST 1.1.

The trial demonstrated a statistically significant improvement in OS. Median OS for patients receiving nivolumab was 10.9 months (95% CI: 9.2, 13.3) compared with 8.4 months (95% CI: 7.2, 9.9) for patients receiving investigator’s choice of taxane chemotherapy (HR: 0.77; 95% CI: 0.62, 0.96; p=0.0189). OS benefit was observed regardless of tumor PD-L1 expression level. The ORR was 19.3% (95% CI: 13.7, 26) in the nivolumab arm versus 21.5% (95% CI: 15.4, 28.8) in the taxane chemotherapy arm, with median response duration of 6.9 months (95% CI: 5.4, 11.1) and 3.9 months (95% CI: 2.8, 4.2), respectively. The trial did not demonstrate an improvement in PFS (HR: 1.1; 95% CI: 0.9, 1.3).

Table of Contents

YOU MAY BE INTERESTED IN

Secretary of the U.S. Department of Health and Human Services Robert F. Kennedy Jr. appeared before the House Energy and Commerce Subcommittee on Health to defend the HHS fiscal year 2026 budget proposal, and faced criticism from several Democratic lawmakers on what they described as a lack of transparency and scientific rigor in the agency’s recent decisions.

The full-scale Russian invasion of Ukraine has devastated the Ukrainian healthcare infrastructure, disrupting cancer care, halting clinical trials, and compounding long-standing systemic challenges.  Even before the war, Ukraine’s oncology system faced major constraints: Limited access to radiotherapy equipment, outdated chemotherapy supply chains, and workforce shortages. The invasion intensified these issues—cancer hospitals were damaged, warehouses destroyed,...

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login